Background
Glioblastoma (GBM) is one of the most aggressive tumors in central nervous system [
1] with a median overall survival less than 15 months due to the very nature of GBM [
2]. The current standard strategy of GBM including maximum safe resection, radiotherapy and the temozolomide (TMZ) chemotherapy are widely applied, however, most GBM patients still develop rapid tumor recurrence within a period of 7 months [
3]. Accumulating evidence indicates that acquired chemoresistance to TMZ is the primary cause of therapy failure thus leads to eventual tumor recurrence and unfavorable prognosis [
4]. Therefore, identifying reliable prognostic biomarker and potential therapeutic targets becomes a major obstacle in GBM treatment.
Treatments targeting kinases have taken researchers into a new insight of anti-tumor strategies, by which the proliferation of multiple cancers are significantly eliminated [
5‐
7]. A wide range of kinases have been identified to be functionally required for tumorigenesis and therapy resistance in GBM [
8]. Besides these kinases which function as oncogenes, there are also a portion of tumor-suppressing kinases promotes aggressive biological behaviors of GBM via eliminated expression or inactivation. Serine/threonine-protein kinase polo like kinase 2 (PLK2) is a key regulator participates in centriole duplication [
9], G1/S phase transition [
10] and synaptic plasticity [
11]. Benetatos et al. [
12] report that PLK2 expression is significantly suppressed in acute myeloid leukemias. It has been proved that CpG island methylation at the 5′- of promoter area induces ectopic expression of PLK2 and promote apoptosis in B-cell malignancies [
13]. Additionally, in acute myeloma cell lines, targeting PLK2 by miR-126 induces the down-regulation of PLK2 and inhibits cell apoptosis and increases cell viability [
14]. Moreover, the same microRNA was closely associated with TMZ resistance according to NoncoRNA database [
15]. However, the potential function of PLK2 in GBM carcinogenesis and chemoresistance remains unclear.
Notch signaling pathway is one of the most conservative pathways that regulates essential processes during cell proliferation, migration, stem cell maintenance, apoptosis and differentiation [
16,
17]. In mammals, there are 4 homologous proteins named Notch1, Notch2, Notch3 and Notch4, function as cytoplasmic receptors by binding to 2 ligands families, including Delta-like (DLL1–4) and Jagged (JAG1–2) [
18,
19]. The interaction between Notch and its ligands triggers a conformational change in the Notch receptor and releases the active form of Notch Intracellular Domain (NICD) into the cytoplasm, which allows the transcription of Notch target genes, including HES1, c-MYC and cyclin D3 [
20,
21]. Previous studies have reported the overexpression of Notch components including DLL1, Notch1 and ASCL1 correlates with a higher grade of glioma and a worse prognosis, indicating an activated Notch signaling is usually associated with more aggressive tumor phenotype [
22‐
24]. Moreover, the overexpression of Notch1 promotes AKT activation, leads to the nuclear localization of NF-κB and β-catenin thus promotes cell migration and invasion [
25]. Additionally, the elevation of several Notch-related genes are found under hypoxic condition and closely associated with poor outcome, indicating that Notch-related genes might hold a prognostic implication [
18]. Interestingly, Purow et al. showed that Notch1 transcriptionally regulates EGFR, which is proved to be highly increased in GBM, through TP53 [
26], Consistently, transcription of Notch signaling mediator genes are significantly overexpressed in the molecular subset of GBM with EGFR amplification [
27]. As Notch signaling is essential for multiple malignancies of GBM, it is crucial to investigate the underlying molecular mechanisms of Notch pathway in GBM.
In this study, we found PLK2 is down-regulated in GBM and the elevation of PLK2 is positively correlated with chemosensitivity and favorable prognosis in GBM patients. Additionally, overexpression of PLK2 attenuated the proliferation and enhanced chemosensitivity of GBM cells. Moreover, we demonstrated that loss of PLK2 induced chemoresistance to TMZ by activation of Notch signaling via transcriptional regulation of HES1 and Notch degradation. Altogether, PLK2-Notch axis could be a prognostical biomarker and potential therapeutic target for TMZ resistant GBM.
Methods and materials
Differential gene expression analysis
Expression profile of GSE68029 [
28] and GSE16011 [
29] were extracted from Gene expression omnibus (GEO). These transcriptome profiles were preprocessed as previously described [
30]. Gene expression datasets of TCGA GBM was extracted from GDC Data Portal (
https://portal.gdc.cancer.gov/). The limma package [
31] was used for identifying the differentially expressed genes in these datasets. The expression difference of individual gene was defined by log
2(Fold change) and adjusted
P value, in which log
2FC < − 1 with an adjusted
P value < 0.05 was defined as a down-regulated gene. Venn diagram was carried out to illustrate the overlapping down-regulated genes in these datasets.
Ethical statement and patient samples
This study was approved by the Scientific Ethics Committee at the First Affiliated Hospital of Xi’an Jiaotong University (approval no. 2016–18). All the patients’ samples used in this study have obtained necessary consent, and all samples were embedded in paraffin blocks as previously described [
30].
Immunohistochemistry (IHC) and global immunohistochemistry score (GIS)
Immunohistochemistry was performed as previously described [
32,
33]. Anti-PLK2 primary antibodies were purchased from Abcam (cat. no. ab71311). Secondary antibodies including Goat anti-rabbit IgG (cat. no. ab97051, Abcam) and goat anti-mouse IgG (cat. no. ab205719, Abcam) were used in this study. Tissues embedded with paraffin were cut into 4-mm sections followed by deparaffinized, rehydrated, and stained with primary antibodies at 4 °C overnight. The slides were then incubated with secondary antibodies and stained with DAB. Consequently, the slides were counterstained with hematoxylin and images were taken under the light microscope.
The global immunohistochemistry score (GIS) was used to measure the relative expression of PLK2 in different samples. GIS was calculated by the following equation: immunoreactivity score = staining intensity score × positive cell score. The staining intensity score was scored as: 0, negative; 1, weakly positive; 2, moderately positive; and 3, strongly positive. The positive cell score was scored as: 0, negative; 1, < 10% positive; 2, 11–50% positive; 3, 51–80% positive; and 4, > 80% positive. Consequently, an immunoreactivity score > 5 was considered as high expression, and ≤ 5 was defined as low expression.
Lentivirus production and transduction
Lentivirus production and transduction were performed as described previously [
30]. The lentiviral overexpression/knockdown PLK2 was designed and synthesized by Genechem (Shanghai, China). These lentiviruses were introduced into U87 and U251 cell lines according to manufacturer’s instruction. Stable clones transduced with PLK2 and shPLK2 were selected for 4 weeks by puromycin. Lentiviral particles packaging the shRNA are targeting PLK2 (5′-TAGTCAAGTGACGGTGCTG-3′) and the scramble control (5′-TTCTCCGAACGTGTCACGT-3′).
Cell culture, in vitro cell proliferation and cell viability assay
GBM cell lines including U87 and U251 were purchased from Cell bank, Type culture collection, Chinese Academy of Sciences (Xi’an China) as previously described [
30]. Cells were cultured in DMEM-F12 containing 10% FBS and antibiotics (1% penicillin and streptomycin). U87 and U251 cells were cultured in a humidified condition containing 5% CO
2 at 37 °C.
For in vitro cell proliferation assay, cells were suspended adequately before seeded into 96-well plates at a density of 1 × 103 cells/well. Cell number was counted by using alamarBlue following the manufacturer’s instruction after indicated treatments.
Cell viability assays were conducted as previously described [
30]. In brief, cell number was calculated by cell counter with trypan blue, cells were then seeded into 96-cell plates after suspended adequately at a density of 2 × 10
3 cells/100 uL per well. After 24 h of culturing, U87 and U251 cell lines received indicated in vitro chemotherapy using corresponding concentration of TMZ. At last, cell number was counted by alamarBlue and IC50 was calculated by SPSS 22.0.
Quantitative RT-PCR (qRT-PCR) and Western blot analysis
The Quantitative RT-PCR assays were conducted as previously described [
30]. In brief, total RNA was extracted using RNeasy mini kits according to the manufacturer’s instruction, and the concentration of RNA was determined by Nanodrop 2000. qRT-PCR was performed following the synthesis of cDNA according to the standard protocols. GAPDH was used as an internal control. Relative mRNA expressions were calculated by 2
-ΔΔt method. The primer sequences were listed as below:
PLK2: forward, 5′-GCTGATGTCTGGCTGTTCATCAG-3′ and reverse, 5′-CTTCCCTGTAGATCTCACA GTG-3′;
HES1: forward, 5′-AGTGAAGCACCTCCGGAAC-3′ and reverse, 5′-TCACCTCGTTCATGCACTC-3′.
c-MYC: forward, 5′- AAACACAAACTTGAACAGCTAC-3′ and reverse, 5′- ATTTGAGGCAGTTTACATTATGG-3′.
p21: forward, 5′- GGCATAGAAGAGGCTGGTGG-3′ and reverse, 5′- ATGGCGCCTGAACAGAAGAA-3′.
Cyclin D3: forward, 5′- AAACTTGGCTGAGCAGAGCA-3′ and reverse, 5′- GAACAGAGCCAGTCTCCACC-3′.
GAPDH: forward, 5′-ACCCAGAAGACTGTGGATGG-3′ and reverse, 5′-TTCAGC TCAGGGATGACCTT-3′.
Western blot analyses were performed as previously described [
32]. Antibodies used in this study were shown as below: Anti-PLK2 primary antibody was purchased from Abcam (cat. no. ab71311). Anti-β-actin antibody was purchased from Abcam (cat. no. ab115777). Anti-NOTCH1, anti-NOTCH2, anti-HES1, anti-c-MYC and anti-cyclin D3 primary antibodies were bought from Cell Signaling Technology (CST) with the catalog number of #4147, #5732, #11988, #18583 and #2936, respectively. Additionally, Anti-Rabbit IgG and Anti-Mouse-IgG were purchased from CST (cat. no. #7074 and #7076, respectively).
Colony formation assays were conducted to detect the tumorigenic potential of U87 and U251 cell lines. Different numbers of stable U87 and U251 cells transduced with lentiviral PLK2 or vector were seeded into 6-well plates under indicating conditions. After cultured for 14 days to form colonies, these cells were fixed with methanol and stained with methylene blue.
The wound healing assay is used to study the migratory ability of U87 and U251 GBM cell lines. Cells were seeded in 6-well plates after adequately suspended. Afterwards, a sterile pipette tip was used to produce a wound line when cells reached the appropriate confluence. These cells were then washed at least 3 times to be cultured in FBS-free medium. Images were taken under inverted microscope at the same location. The leading edges were marked by white lines, and the relative distance of the borders was measure by Image J software.
The construction of TMZ resistant glioma cell lines
To construct TMZ resistant cell lines, U87 and U251 were gradually treated with increasing concentration of TMZ. In brief, the beginning concentration of TMZ was set according to the IC50 of U87 and U251 naïve cells. The medium was changed every 2 days to keep the concentration of TMZ at a stable level for 2 weeks. Afterwards, new IC50 was calculated using the pre-treated cell lines and the process was continued until the IC50 of TMZ reached the amount of 500uM. These cells were then used for subsequent experiments.
In vivo intracranial xenograft tumor models
The usage of experimental animals in this study was approved by the Ethics Committee of the School of Medicine, Xi’an Jiaotong University (approval no. 2016–085). In vivo xenograft model was constructed by using 6-week-old female nude mice. U87 and U251 cells transduced with indicating lentiviruses was suspended and diluted to the density of 1 × 105 cells in 2 uL PBS then slowly injected into the nude mice brains. Each group of treatment contains five mice, and they were monitored until the following symptoms were observed: unsteady gait, arched back, more than 10% weight loss or leg paralysis.
Flow cytometry
Flow cytometry assays were performed as previously described [
30]. U87 TMZ resistant cells were transfected with either empty vector or plk2 overexpression lentivirus then treated with 200uM TMZ for 24 h. DMSO were used as a negative control. The Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis kit was used strictly following the manufacturer’s protocol to measure the cell apoptotic rate.
Gene set enrichment analysis (GSEA)
The transcriptome profiles of previously mentioned datasets were read into R programming and preprocessed by background correction, gene ID transformation and normalization. These data were then ordered by the expression level of PLK2 to divide all samples into two groups (PLK2
high and PLK2
low) by quartile cutoff. Afterwards, these profiles were uploaded into the GSEA software [
34] strictly following the guideline of the software to elucidate the enriched KEGG pathways that are significantly enriched in PLK2
low groups with the number of permutations set at 1000.
Glutathione S-transferase (GST) pull-down assay
The ubiquitination level of Notch1 was determined by GST-mediated pull-down assays (Thermo Scientific, Rockford, IL). Briefly, GST-tagged Notch1 was transfected into indicated cell lines (isogenic PLK2 overexpressed cells or their negative control) by lipofectamine according to manufacturer’s instruction. After 24 h, cell lysates were collected and incubated with GST beads for 1 h. Then, GST complexes were washed extensively with lysate buffer and used to perform western blot assays.
Statistical analysis
All the results in this study are exhibited as mean ± SD (Standard deviation) as described previously [
35]. The number of independent replications is presented in the figure legends. Two-tailed
t tests were conducted to evaluate statistical differences and One-way ANOVA following Dunnett’s post-test was used to compare the statistics in more than two groups. Kaplan-Meier survival analyses were performed using log-rank test. In addition, all statistical analysis was performed by GraphPad Prism 7 or SPSS 22.0 software, and statistical significance was defined as a two-sided
P value less than .05 unless specifically indicated.
Discussion
Most targeted anti-GBM treatments including cytotoxic and radiation therapies are encumbered by the development of resistance in GBM cells [
38]. The limited effectiveness of TMZ in GBM has been correlated with its inability to induce adequate level of apoptosis thus leads to acquired chemoresistance [
39]. Notably, resistance is a complicated process involving deficiencies in apoptosis induction, activation of multiple signaling pathways and expulsion of drug through cell membrane transporters [
38,
40]. Although novel therapeutic targets have been found in the past several decades, the overall survival of GBM patients remain dismal due to the tumor recurrence followed by chemoresistance [
3,
41]. Therefore, developing new biomarkers and therapeutic strategies targeting TMZ resistance in GBM are in urgent need.
Increasing evidence has identified that the aberrant expression of tumor-related kinases is closely connected to the progression, therapeutic resistance or recurrence of various cancers [
42‐
45]. The polo-like kinases (PLKs) are among these protein kinases that control multiple complex process of centriole duplication [
46]. The improvement of the basic biology of PLK1 have helped us to deeply understand its function in regulating the cell cycle [
47], and various observations on the upregulation of PLK1 in human cancers also provided researchers a new anti-tumor target [
48,
49]. For instance, the inhibition of PLK1 was reported to cause cell cycle arrest and lead to cell death in glioblastoma [
50]. Unlike PLK1, PLK2 functions as a tumor suppressor in some cancer types. In a wide range of B-cell neoplasms, PLK2 was epigenetically silenced due to the aberrant CpG methylation [
13]. However, recent bioinformatic approaches demonstrated that hypermethylation of PLK2 might lead to a favorable outcome in GBM patients, which need to be further confirmed by experimental studies [
51]. Additionally, the ectopic expression of PLK2 in Burkitt lymphoma cells increased the apoptosis rate, indicating the tumor-suppressing function of PLK2 in human cancers [
13]. Moreover, another indirect evidence for this tumor suppressor was discovered in a study of acute myeloma. This study demonstrated that targeting PLK2 by miR-126 inhibits cell apoptosis and increases cell viability, indicating the silencing of PLK2 enhances the cell viability in acute myeloma cell lines [
14]. However, the functional role of PLK2 in GBM chemoresistance has not been fully elucidated. In this study, we demonstrated that PLK2 is down-regulated in TMZ resistant GBM cells and it is negatively associated with clinical outcome. Furthermore, we demonstrated that PLK2 overexpression attenuated TMZ resistance in GBM cell lines by destabilizing NOTCH1.
The cleavage of notch receptor by γ-secretase after binding of ligands like jagged or delta family leads to the translocation of Notch intracellular domain (NICD) to the nucleus, thereby activating notch-related downstream targets [
52]. Afterwards, notch signaling is terminated by triggering ubiquitinated degradation of NICD PEST domain with the absence of SCF E3 ubiquitin ligase [
53,
54]. And the recognition of NICD by this ligase is mainly mediated by FBXW7, which binds to the phosphorylated NICD to recruit E3 ubiquitin ligase [
55]. Mutations within the PEST domain of NICD or mutation of FBXW7 result in NICD stabilization, thereby leading to abnormal activation of its downstream targets [
54‐
56]. Accumulating evidence shows the phosphorylation of NICD enhances FBXW7 binding, indicating a potential mechanism to suppress notch signaling by NICD ubiquitination [
54]. Moreover, Fryer et al. [
57] clarified inhibition of CDKs by small molecule inhibitors results in the stabilization of NICD, leading to higher NICD levels and half-life, thereby slowing down oscillations in the segmentation clock. These previous studies indicated that the activation or maintenance of notch signaling are partially controlled by the interaction between kinases and NICD. Although the Notch signaling has been clarified to be involved in the progression of various cancers, the correlation of Notch1 and PLK2 has not been investigated. Therefore, we hypothesize that PLK2 may act as a suppressor of notch signaling by phosphorylating NICD. To this end, we demonstrated that PLK2 suppressed Notch signaling pathway by destabilizing activated Notch1 thus lead to the down-regulation of its downstream targets including HES1. Moreover, the simultaneous overexpression of PLK2 and HES1 partially rescued the suppression of PLK2 on Notch signaling pathway and its biological functions. In addition, the degradation of activated Notch1 was observed when PLK2 was overexpressed, indicating that PLK2 might phosphorylate the Notch1 thus lead to the ubiquitination of activated Notch1. However, further experiments are needed to investigate the mechanism of how PLK2 phosphorylate Notch1.
It has been widely proved that Notch signaling is at the center of a signaling network, which also includes pathways such as PI3K/AKT, NF-κB, STAT3, Hedgehog, and Wnt/β-catenin, which are involved in cell differentiation, cell growth, and survival. Therefore, targeting Notch signaling might be a potential therapeutic target for GBM particularly for those which are resistant to TMZ. Although PLK2-Notch-targeted monotherapy seems to be promising, a better accomplishment is to combine Notch inhibitors with other molecules or chemotherapeutic agents like bevacizumab and TMZ, respectively. Additionally, Meng et al. [
58] found the simultaneous inhibition of EGFR and MET signaling by a novel nanoparticle enhanced TMZ chemosensitivity in TMZ-resistant cell lines, indicating the significance of targeting different pathways that contribute to chemoresistance. Although the underlying roles of PLK2 in chemoresistance are well discussed in this study, additional molecular biological investigations are still required for evaluating the clinical significance of PLK2 in chemotherapy. Notably, although the samples from our center indicated that there might be a correlation between PLK2 expression and clinical degree of glioma, data from other databases including TCGA, CGGA, Rembrandt indicated an ambiguous correlation between PLK2 and tumor grade or cancer pathological subtypes. This may be due to the small scale of our samples and no conclusion related to the correlation between WHO grades and PLK2 expression could be made from this finding. Moreover, integrated multi-central data and meta analyses are needed to further confirm this finding. Also, how PLK2 interacts with NOTCH1 to further regulate notch signaling and whether PLK2-induced chemosensitivity solely depends on its regulation on notch signaling remain unclear. Further investigations like GST pull-down and immunoprecipitation assays are needed to study the ubiquitination of Notch1 caused by PLK2 overexpression. Moreover, alteration of a single candidate biomarker might bring unpredictable effects due the heterogeneity of GBM. Therefore, it is crucial to evaluate GBM patients by more integrated strategies before clinical management.
Conclusion
In this study, we analyzed the transcriptome profiles of different public databases including Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) to identify PLK2 as a candidate kinase in regulating TMZ resistance in GBM. Notably, depressed PLK2 expression was found to be strongly related to poor prognosis in GBM patients. Next, experimental analyses were performed to clarify the underlying role of PLK2 by lentiviral transduction, and we demonstrated that PLK2 promoted chemosensitivity of GBM cell lines to TMZ by in vitro biological assays. Moreover, the xenograft mouse model illustrated that PLK2-OE prolonged the overall survival of tumor-bearing mice and consistently increased the chemosensitivity to TMZ. In addition, Notch signaling was the only overlapped signaling pathway which negatively correlated with PLK2 in different databases according to the result of GSEA analyses. We further confirmed this finding by molecular biological assays and demonstrated that PLK2 suppressed Notch signaling pathway and its biological functions by destabilizing activated Notch1.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.